The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide； b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical； c) the amino acid position A8 is occupied by a histidine radical； d) the amino acid position A21 is occupied by a glycine radical； and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.
